Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report.
作者信息
Álvarez Otero J, Sanjurjo Rivo A, Lamas Ferreiro J L, de la Fuente Aguado J
机构信息
Judith Álvarez Otero, C/Tarragona, 2, 4º A. CP: 36211. Vigo (Pontevedra). Spain.
出版信息
Rev Esp Quimioter. 2019 Jun;32(3):276-277. Epub 2019 Apr 30.
Abstract
摘要
相似文献
1
Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report.达巴万星治疗进展缓慢的甲氧西林敏感金黄色葡萄球菌性脓性肌炎：一例报告
Rev Esp Quimioter. 2019 Jun;32(3):276-277. Epub 2019 Apr 30.
2
[Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].[达巴万星对耐甲氧西林表皮葡萄球菌所致人工髋关节感染的长期治疗作用]
Rev Esp Quimioter. 2019 Apr;32(2):203-204. Epub 2019 Mar 13.
3
Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection.在耐甲氧西林金黄色葡萄球菌感染治疗期间出现对替考拉宁的耐药性。
J Antimicrob Chemother. 2002 Feb;49(2):423-4. doi: 10.1093/jac/49.2.423.
4
Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.达巴万星治疗耐甲氧西林金黄色葡萄球菌心内膜炎失败
J Clin Pharm Ther. 2018 Feb;43(1):101-103. doi: 10.1111/jcpt.12580. Epub 2017 Jun 19.
5
[Pyomyositis of hip obturator muscles].[闭孔肌脓性肌炎]
Cir Pediatr. 2006 Oct;19(4):241-3.
6
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).美国医院儿科患者皮肤和皮肤结构感染的革兰阳性临床分离株检测达巴万星的活性（2014-2015 年）。
J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.
7
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).达巴万星对 2011-2016 年美国和欧洲医院引起骨和关节感染的革兰阳性临床分离株的体外活性。
Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.
8
Positron emission tomography in the diagnosis of disseminated pyomyositis due to PVL-negative methicillin-resistant Staphylococcus aureus.正电子发射断层扫描在诊断由PVL阴性耐甲氧西林金黄色葡萄球菌引起的播散性脓性肌炎中的应用
QJM. 2013 May;106(5):485-6. doi: 10.1093/qjmed/hcs088. Epub 2012 Jun 11.
9
Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.单独使用达巴万星和达巴万星联合利福平对假体感染模型中金葡菌的活性。
Int J Antimicrob Agents. 2013 Sep;42(3):220-5. doi: 10.1016/j.ijantimicag.2013.05.019. Epub 2013 Jul 20.
10
Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.达巴万星治疗冠状动脉搭桥术后深部胸骨伤口耐甲氧西林金黄色葡萄球菌感染：一例报告
J Cardiothorac Surg. 2018 Jan 5;13(1):3. doi: 10.1186/s13019-017-0690-5.
引用本文的文献
1
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.在强化门诊抗菌治疗时代下的达巴万星实际应用：超越获批适应证，关注未满足临床需求的审慎评估。
Drug Des Devel Ther. 2021 Aug 3;15:3349-3378. doi: 10.2147/DDDT.S313756. eCollection 2021.
本文引用的文献
1
Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus .亚抑菌浓度的达巴万星可减弱甲氧西林敏感和耐甲氧西林金黄色葡萄球菌产毒素。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01090-17. Print 2017 Nov.
2
Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).达巴万星对在美国和欧洲医院引起已记录皮肤及皮肤结构感染的革兰氏阳性临床分离株活性的最新研究（2011 - 2013年）
J Antimicrob Chemother. 2016 Jan;71(1):276-8. doi: 10.1093/jac/dkv303. Epub 2015 Oct 7.
3
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.达巴万星的延长给药及在骨骼和关节组织中的分布。
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.
4
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.美国传染病学会关于皮肤和软组织感染的诊断和管理实践指南：2014 年更新。
Clin Infect Dis. 2014 Jul 15;59(2):147-59. doi: 10.1093/cid/ciu296. Epub 2014 Jun 18.
5
Surveillance of dalbavancin potency and spectrum in the United States (2012).美国达巴万星效力与抗菌谱监测（2012年）
Diagn Microbiol Infect Dis. 2013 May;76(1):122-3. doi: 10.1016/j.diagmicrobio.2013.01.003. Epub 2013 Feb 20.
6
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.达巴万星对全球81673株革兰氏阳性细菌分离株的活性。
Antimicrob Agents Chemother. 2009 Mar;53(3):1260-3. doi: 10.1128/AAC.01453-08. Epub 2009 Jan 5.
7
Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.达巴万星：一种新型的每周一次的脂糖肽类抗生素。
Clin Infect Dis. 2008 Feb 15;46(4):577-83. doi: 10.1086/526772.
8
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.达巴万星在血浆和皮肤疱液中的药代动力学。
J Antimicrob Chemother. 2007 Sep;60(3):681-4. doi: 10.1093/jac/dkm263. Epub 2007 Jul 12.
9
Origin, structure, and activity in vitro and in vivo of dalbavancin.达巴万星的来源、结构及其体外和体内活性
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii15-20. doi: 10.1093/jac/dki005.
Zotero 插件